 CRANFORD, N.J., Jan. 04, 2021 GLOBE NEWSWIRE -- Enzon Pharmaceuticals, Inc. OTC:ENZN announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Companys Chief Executive Officer effective February 26, 2021. Andy joined Enzon in 2010 as Vice-President and General Counsel and has served as CEO since 2016. Upon Andys retirement, Richard L. Feinstein, Enzons Chief Financial Officer, will also assume the role of Chief Executive Officer and Secretary, as well as remain the Companys Chief Financial Officer. Mr. Rackear will be available as a consultant to the Company following his retirement, as may be needed. 